<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trimeprazine (alimemazine) (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trimeprazine (alimemazine) (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Trimeprazine (alimemazine) (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="108204" href="/d/html/108204.html" rel="external">see "Trimeprazine (alimemazine) (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52865497"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Panectyl</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46324347"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiemetic;</li>
<li>
                        Antihistamine;</li>
<li>
                        Phenothiazine Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F46321459"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58568a15-a335-418c-bfd9-436ba83c629b">Cough, pruritus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:2em;">
<b>Cough, pruritus:</b>
<b>Note:</b> Initiate at low dosage and titrate as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>: 2.5 mg to 5 mg twice daily after meals plus 5 mg at bedtime; for predominantly nocturnal symptoms, use 5 mg to 10 mg once daily at bedtime; for severe pruritus, up to 80 mg/day in divided doses may be considered for hospitalized patients only.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991585"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988773"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F46321460"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution due to increased risk of adverse effects.</p></div>
<div class="block dop drugH1Div" id="F46321458"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58568a15-a335-418c-bfd9-436ba83c629b">Cough, pruritus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough, pruritus:</b>
<b>Note:</b> Initiate at low dosage and titrate as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 12 years: Oral: Initial: 2.5 mg to 5 mg once daily at bedtime; if necessary, administer additional dosage of 2.5 mg twice daily after meals; maximum: 15 mg/day</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Refer to adult dosing.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193019"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193020"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F46420493"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, ECG changes, syncope, torsades de pointes</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Akathisia, depression, drowsiness (dose related), dystonia, mood elevation, nightmares, Parkinsonian-like syndrome, seizure, tardive dyskinesia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, gastric distress, nausea, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (transient), neuromuscular reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion</p>
<p style="text-indent:-2em;margin-left:2em;">1%, postmarketing, and/or case reports: Agranulocytosis (reversible), atrioventricular block, dermatitis, extrapyramidal reaction, leukopenia, muscle rigidity, muscle spasticity, skin rash, supraventricular tachycardia, tremor, ventricular fibrillation, ventricular tachycardia</p></div>
<div class="block coi drugH1Div" id="F248123"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of severe allergic reaction to trimeprazine, any component of the formulation, or other phenothiazines; history of blood dyscrasias related to trimeprazine or other phenothiazines; states of CNS depression due to barbiturates, alcohol, opioids, or analgesics; use in children &lt;2 years of age.</p></div>
<div class="block war drugH1Div" id="F248111"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: May alter cardiac conduction; ECG changes including QT interval prolongation, ST depression, and T or U wave changes may be noted. Atrioventricular (AV) block, supraventricular tachycardia, ventricular tachycardia and fibrillation have been observed (possibly dose-dependent); elderly patients and/or those with cardiac disease, hypokalemia, or taking concomitant tricyclic antidepressants may be at increased risk. Torsades de pointes, ventricular fibrillation, cardiac arrest, and sudden death have occurred (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Drowsiness is common but may subside within 1 to 3 weeks; elderly and/or those receiving doses ≥30 mg/day may have higher incidence. Initiate therapy at reduced dosage and gradually titrate to minimize drowsiness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extrapyramidal effects: May cause extrapyramidal symptoms, including tremor, spasticity, painful skeletal muscle contractions, dystonia, akathisia, and tardive dyskinesia; effects are often dose dependent and/or associated with therapy duration. Acute reactions may occur within 4 days in children and young adults; parkinsonism may occur weeks or months after therapy initiation in adults and the elderly. Discontinue use for neuromuscular reactions; do not reinitiate in children or pregnant women. May consider therapy reinitiation in other patients at a reduced dosage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment and/or jaundice.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures or seriously ill or dehydrated children.</p>
<p style="text-indent:0em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; may be at increased risk for developing adverse effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">•Antiemetic effects: May mask signs of other clinical conditions (eg, intestinal obstruction, brain tumor).</p></div>
<div class="block geq drugH1Div" id="F53040708"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52865498"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Panectyl: 2.5 mg, 5 mg</p></div>
<div class="block adm drugH1Div" id="F46321464"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Administration after meals may reduce the incidence of adverse effects.</p></div>
<div class="block admp drugH1Div" id="F52756184"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer at bedtime; if twice daily dosing is used, administer after meals.</p></div>
<div class="block use drugH1Div" id="F248120"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough:</b> Treatment of cough.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus:</b> Treatment of pruritus.</p></div>
<div class="block cyt drugH1Div" id="F13300178"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F248114"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Trimeprazine may enhance the CNS depressant effect of ARIPiprazole. Trimeprazine may increase the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: Trimeprazine may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: May enhance the CNS depressant effect of Trimeprazine. Trimeprazine may increase the serum concentration of QUEtiapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F46321118"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Use is not recommended during pregnancy. If neuromuscular reactions occur in pregnant women, discontinue and do not reinitiate.</p></div>
<div class="block brc drugH1Div" id="F46321119"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Phenothiazines are excreted in human milk; excretion of trimeprazine is not known.</p></div>
<div class="block mop drugH1Div" id="F248117"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mental status; vital signs (as clinically indicated).</p></div>
<div class="block pha drugH1Div" id="F248110"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Phenothiazine derivative with reduced central effects and enhanced antipruritic and antihistaminic effects; also has marked sedative, antiemetic, antispasmodic, and antiserotonin properties. Influence on the autonomic nervous system is weak.</p></div>
<div class="block phk drugH1Div" id="F248122"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Delayed by food.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: &gt;90% bound to plasma proteins (Hu 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: &lt;70% (Hu 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: 4.78 hours ± 0.59 hours (Hu 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak serum concentration: Tablet: 4.5 ± 0.43 hours (Hu 1986).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58202156"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Variargil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alfresed | Alimemazine | Trimeprazine | Vallergan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alimezine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cooljin | Crazin | Theralene</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Theralen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Theralen</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nedeltran</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alimemazine | Teraligen | Teralygen | Teralygen retard | Teralygen valenta | Theralen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Theralen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Theralene</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alimezine | Trimeprazine tartrate</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">AcezinDHG | Aginmezin | Tamerlane | Tuxsinal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Vallergan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2871150">
<a name="2871150"></a>Hu OY, Gfeller E, Perrin JH, et al. Relative bioavailability of trimeprazine tablets investigated in man using HPLC with electrochemical detection. <i>J Pharm Pharmacol</i>. 1986;38(3):172-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimeprazine-alimemazine-united-states-not-available-drug-information/abstract-text/2871150/pubmed" id="2871150" target="_blank">2871150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Panectyl.1">
<a name="Panectyl.1"></a>Panectyl (trimeprazine) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; October 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 109410 Version 121.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
